465 related articles for article (PubMed ID: 26053561)
1. ALK-positive primary cutaneous T-cell-lymphoma (CTCL) with unusual clinical presentation and aggressive course.
Wehkamp U; Oschlies I; Nagel I; Brasch J; Kneba M; Günther A; Klapper W; Weichenthal M
J Cutan Pathol; 2015 Nov; 42(11):870-7. PubMed ID: 26053561
[TBL] [Abstract][Full Text] [Related]
2. Intralymphatic cutaneous anaplastic large cell lymphoma/lymphomatoid papulosis: expanding the spectrum of CD30-positive lymphoproliferative disorders.
Samols MA; Su A; Ra S; Cappel MA; Louissant A; Knudson RA; Ketterling RP; Said J; Binder S; Harris NL; Feldman AL; Kim J; Kim YH; Gratzinger D
Am J Surg Pathol; 2014 Sep; 38(9):1203-11. PubMed ID: 24805854
[TBL] [Abstract][Full Text] [Related]
3. Recurrent ALK-negative anaplastic large T-cell lymphoma presenting as necrotizing vasculitis.
Nambudiri VE; Aboutalebi A; Granter SR; Saavedra A
Am J Dermatopathol; 2013 Jun; 35(4):512-6. PubMed ID: 23291583
[TBL] [Abstract][Full Text] [Related]
4. ALK-positive (2p23 rearranged) anaplastic large cell lymphoma with localization to the skin in a pediatric patient.
Pulitzer M; Ogunrinade O; Lin O; Steinherz P
J Cutan Pathol; 2015 Mar; 42(3):182-187. PubMed ID: 25404214
[TBL] [Abstract][Full Text] [Related]
5. Fatal ALK-negative systemic anaplastic large cell lymphoma presenting with disseminated cutaneous dome-shaped papules and nodules.
Bird JE; Leitenberger JJ; Solomon A; Blauvelt A; Hopkins S
Dermatol Online J; 2012 May; 18(5):5. PubMed ID: 22630575
[TBL] [Abstract][Full Text] [Related]
6. Complete response in a critically ill patient with ALK-negative anaplastic large cell lymphoma treated with single agent brentuximab-vedotin.
Oregel KZ; Everett E; Zhang X; Nagaraj G
Expert Rev Anticancer Ther; 2016; 16(3):279-83. PubMed ID: 26809026
[TBL] [Abstract][Full Text] [Related]
7. Anaplastic lymphoma kinase-positive anaplastic large cell lymphoma: current and future perspectives in adult and paediatric disease.
Eyre TA; Khan D; Hall GW; Collins GP
Eur J Haematol; 2014 Dec; 93(6):455-68. PubMed ID: 24766435
[TBL] [Abstract][Full Text] [Related]
8. High expression of Dicer reveals a negative prognostic influence in certain subtypes of primary cutaneous T cell lymphomas.
Valencak J; Schmid K; Trautinger F; Wallnöfer W; Muellauer L; Soleiman A; Knobler R; Haitel A; Pehamberger H; Raderer M
J Dermatol Sci; 2011 Dec; 64(3):185-90. PubMed ID: 21937200
[TBL] [Abstract][Full Text] [Related]
9. Brentuximab vedotin and crizotinib in anaplastic large-cell lymphoma.
Foyil KV; Bartlett NL
Cancer J; 2012; 18(5):450-6. PubMed ID: 23006951
[TBL] [Abstract][Full Text] [Related]
10. Anaplastic large cell lymphoma, ALK-negative.
Ferreri AJ; Govi S; Pileri SA; Savage KJ
Crit Rev Oncol Hematol; 2013 Feb; 85(2):206-15. PubMed ID: 22789917
[TBL] [Abstract][Full Text] [Related]
11. Variable loss of CD30 expression by immunohistochemistry in recurrent cutaneous CD30+ lymphoid neoplasms treated with brentuximab vedotin.
Goyal A; Patel S; Goyal K; Morgan EA; Foreman RK
J Cutan Pathol; 2019 Nov; 46(11):823-829. PubMed ID: 31286556
[TBL] [Abstract][Full Text] [Related]
12. Primary cutaneous T-cell lymphoma occurring after organ transplantation.
Ravat FE; Spittle MF; Russell-Jones R
J Am Acad Dermatol; 2006 Apr; 54(4):668-75. PubMed ID: 16546591
[TBL] [Abstract][Full Text] [Related]
13. Brentuximab-vedotin in combination with cyclophosphamide, doxorubicin, prednisolone for the treatment of aggressive CD30-positive cutaneous T-cell lymphomas.
Ribereau-Gayon E; Donzel M; Pham F; Romain-Scelle N; Perier-Muzet M; Balme B; Traverse-Glehen A; Ghesquières H; Dalle S
Leuk Lymphoma; 2023; 64(8):1424-1432. PubMed ID: 37255021
[TBL] [Abstract][Full Text] [Related]
14. Brentuximab vedotin therapy for CD30-positive cutaneous T-cell lymphoma: a targeted approach to management.
Scarisbrick JJ
Future Oncol; 2017 Nov; 13(27):2405-2411. PubMed ID: 28805086
[TBL] [Abstract][Full Text] [Related]
15. Cutaneous T-cell lymphomas (including rare subtypes). Current concepts. II.
Paulli M; Berti E
Haematologica; 2004 Nov; 89(11):1372-88. PubMed ID: 15531460
[TBL] [Abstract][Full Text] [Related]
16. Primary cutaneous and systemic anaplastic large cell lymphoma: clinicopathologic aspects and therapeutic options.
Querfeld C; Khan I; Mahon B; Nelson BP; Rosen ST; Evens AM
Oncology (Williston Park); 2010 Jun; 24(7):574-87. PubMed ID: 20669794
[TBL] [Abstract][Full Text] [Related]
17. Characteristics of cutaneous lymphomas in Osaka, Japan (1988-1999) based on the European Organization for Research and Treatment of Cancer classification.
Nagasawa T; Miwa H; Nakatsuka S; Itami S; Yoshikawa K; Aozasa K
Am J Dermatopathol; 2000 Dec; 22(6):510-4. PubMed ID: 11190442
[TBL] [Abstract][Full Text] [Related]
18. A small cell variant of ALK-positive, CD8-positive anaplastic large cell lymphoma with primary subcutaneous presentation mimicking subcutaneous panniculitis-like T-cell lymphoma.
Wang E; Papalas J; Siddiqi I; Stoecker M; Rehder C; Sebastain S; Burchette J; Huang Q
Pathol Res Pract; 2011 Aug; 207(8):522-6. PubMed ID: 21763080
[TBL] [Abstract][Full Text] [Related]
19. Intravascular ALK-negative anaplastic large cell lymphoma with localized cutaneous involvement and an indolent clinical course: toward recognition of a distinct clinicopathologic entity.
Metcalf RA; Bashey S; Wysong A; Kim J; Kim YH; Gratzinger D
Am J Surg Pathol; 2013 Apr; 37(4):617-23. PubMed ID: 23480896
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
